title: Recombinant hCG (OVIDREL) and recombinant interferon-beta1a (REBIF) (No. 13 in a series of articles to promote a better understanding of the use of genetic engineering).
authors.affiliation: Serono International SA, 15 bis Chemin des Mines, CH-1202 Geneva, Switzerland. daniela.piani@serono.com
authors.forename: D
authors.initials: D
authors.lastname: Piani
authors.forename: J P
authors.initials: JP
authors.lastname: Malkowski
mesh_terms: D000818:Animals; D004926:Escherichia coli / Q000235:genetics; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000235:genetics* / Q000627:therapeutic use*; D008322:Mammals; D009103:Multiple Sclerosis / Q000188:drug therapy; D015202:Protein Engineering / Q000379:methods*; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D016899:Interferon-beta; D000068556:Interferon beta-1a